Real-World Evidence for Potential Suicidality Risk with Glucagon-Like Peptide-1 Receptor Agonists

Real-World Evidence for Potential Suicidality Risk with Glucagon-Like Peptide-1 Receptor Agonists
This project will estimate the incidence of new onset suicidality among adults following initiation of a monotherapy glucagon-like peptide-1 receptor agonist (GLP-1RA) medication and to investigate the risk of suicidality with GLP-1RA medications among new users of a monotherapy GLP-1RA drug.
Funder: KPNC Community Health

0